In accordance with the 2024 NCCN Guidelines, the management of nonmetastatic breast cancer necessitates a multidisciplinary approach, emphasizing the judicious application of systemic therapy. For patients with early-stage disease, neoadjuvant or adjuvant chemotherapy, endocrine therapy, and targeted therapy are considered based on tumor biology and patient-specific factors. This comprehensive review examines the evidence supporting the use of these systemic therapies, highlighting the importance of integrating clinical, pathological, and molecular characteristics to inform treatment decisions and optimize outcomes for patients with nonmetastatic breast cancer.